Original Study| Volume 15, ISSUE 6, P733-741.e1, December 2017

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer



      Abiraterone acetate (AA) inhibits androgen biosynthesis and prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) when combined with prednisone (P). Resistance to therapy remains incompletely understood. In this open-label, single-arm, multicenter phase II study we investigated the clinical benefit of increasing the dose of AA at the time of resistance to standard-dose therapy.

      Patients and Methods

      Eligible patients had progressive mCRPC and started AA 1000 mg daily and P 5 mg twice daily. Patients who achieved any prostate-specific antigen (PSA) decline after 12 weeks of therapy continued AA with P until PSA or radiographic progression. At progression, AA was increased to 1000 mg twice daily with unchanged P dosing. Patients were monitored for response to therapy for a minimum of 12 weeks or until PSA or radiographic progression. The primary end point was PSA decline of at least 30% after 12 weeks of therapy at the increased dose of AA.


      Forty-one patients were enrolled from March 2013 through March 2014. Thirteen men experienced disease progression during standard-dose therapy and were subsequently treated with AA 1000 mg twice per day. Therapy was well tolerated. No PSA declines ≥ 30% nor radiographic responses were observed after 12 weeks of dose-escalated therapy. Higher baseline dehydroepiandrosterone levels, lower circulating tumor cell burden, and higher pharmacokinetic levels of abiraterone and abiraterone metabolites were associated with response to standard-dose therapy.


      Increasing the dose of abiraterone at the time of resistance has limited clinical utility and cannot be recommended. Lower baseline circulating androgen levels and interpatient pharmacokinetic variance appear to be associated with primary resistance to AA with P.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Holzbeierlein J.
        • Lal P.
        • LaTulippe E.
        • et al.
        Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.
        Am J Pathol. 2004; 164: 217-227
        • Anantharaman A.
        • Friedlander T.W.
        Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: a review.
        Urol Oncol. 2016; 34: 356-367
        • Ryan C.J.
        • Smith M.R.
        • de Bono J.S.
        • et al.
        Abiraterone in metastatic prostate cancer without previous chemotherapy.
        N Engl J Med. 2013; 368: 138-148
        • de Bono J.S.
        • Logothetis C.J.
        • Molina A.
        • et al.
        Abiraterone and increased survival in metastatic prostate cancer.
        N Engl J Med. 2011; 364: 1995-2005
        • Attard G.
        • Reid A.H.
        • Yap T.A.
        • et al.
        Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
        J Clin Oncol. 2008; 26: 4563-4571
        • Ryan C.J.
        • Halabi S.
        • Ou S.S.
        • et al.
        Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
        Clin Cancer Res. 2007; 13: 2030-2037
        • Scher H.I.
        • Halabi S.
        • Tannock I.
        • et al.
        Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
        J Clin Oncol. 2008; 26: 1148-1159
      1. Alyamani M, Li Z, Upadhyay SK, Anderson DJ, Auchus RJ, Sharifi N. Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column. J Steroid Biochem Mol Biol, Published online April 7, 2016;

        • Friedlander T.W.
        • Ngo V.T.
        • Dong H.
        • et al.
        Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
        Int J Cancer. 2014; 134: 2284-2293
        • Premasekharan G.
        • Gilbert E.
        • Okimoto R.A.
        • et al.
        An improved CTC isolation scheme for pairing with downstream genomics: demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.
        Cancer Lett. 2016; 380: 144-152
        • Anantharaman A.
        • Friedlander T.
        • Lu D.
        • et al.
        Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
        BMC Cancer. 2016; 16: 744
        • Li Z.
        • Alyamani M.
        • Li J.
        • et al.
        Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
        Nature. 2016; 533: 547-551
        • Li Z.
        • Bishop A.C.
        • Alyamani M.
        • et al.
        Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
        Nature. 2015; 523: 347-351
      2. Kalantari E, Asgari M, Nikpanah S, Salarieh N, Asadi Lari MH, Madjd Z. Co-expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas. Pathol Oncol Res, Published online January 12, 2017;

        • Beltran H.
        • Rickman D.S.
        • Park K.
        • et al.
        Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
        Cancer Discov. 2011; 1: 487-495
        • Cai C.
        • Chen S.
        • Ng P.
        • et al.
        Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
        Cancer Res. 2011; 71: 6503-6513
        • Friedlander T.W.
        • Roy R.
        • Tomlins S.A.
        • et al.
        Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.
        Cancer Res. 2012; 72: 616-625
        • Taylor B.S.
        • Schultz N.
        • Hieronymus H.
        • et al.
        Integrative genomic profiling of human prostate cancer.
        Cancer Cell. 2010; 18: 11-22
        • Taplin M.E.
        • Rajeshkumar B.
        • Halabi S.
        • et al.
        Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
        J Clin Oncol. 2003; 21: 2673-2678
        • Azad A.A.
        • Volik S.V.
        • Wyatt A.W.
        • et al.
        Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer.
        Clin Cancer Res. 2015; 21: 2315-2324
        • Ceraline J.
        • Cruchant M.D.
        • Erdmann E.
        • et al.
        Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.
        Int J Cancer. 2004; 108: 152-157
        • Chen G.
        • Wang X.
        • Zhang S.
        • et al.
        Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics.
        Prostate. 2005; 63: 395-406
        • Bergerat J.P.
        • Ceraline J.
        Pleiotropic functional properties of androgen receptor mutants in prostate cancer.
        Hum Mutat. 2009; 30: 145-157
        • Li W.
        • Cavasotto C.N.
        • Cardozo T.
        • et al.
        Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function.
        Mol Endocrinol. 2005; 19: 2273-2282
        • Dehm S.M.
        • Schmidt L.J.
        • Heemers H.V.
        • Vessella R.L.
        • Tindall D.J.
        Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.
        Cancer Res. 2008; 68: 5469-5477
        • Antonarakis E.S.
        • Lu C.
        • Wang H.
        • et al.
        AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
        N Engl J Med. 2014; 371: 1028-1038
        • Watson P.A.
        • Arora V.K.
        • Sawyers C.L.
        Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.
        Nat Rev Cancer. 2015; 15: 701-711
        • Arora V.K.
        • Schenkein E.
        • Murali R.
        • et al.
        Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
        Cell. 2013; 155: 1309-1322
        • Mo Q.
        • Lu S.F.
        • Simon N.G.
        Dehydroepiandrosterone and its metabolites: differential effects on androgen receptor trafficking and transcriptional activity.
        J Steroid Biochem Mol Biol. 2006; 99: 50-58
        • Kim W.
        • Zhang L.
        • Wilton J.H.
        • et al.
        Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
        Clin Cancer Res. 2014; 20: 6269-6276
        • de Bono J.S.
        • Scher H.I.
        • Montgomery R.B.
        • et al.
        Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
        Clin Cancer Res. 2008; 14: 6302-6309
        • Scher H.I.
        • Heller G.
        • Molina A.
        • et al.
        Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.
        J Clin Oncol. 2015; 33: 1348-1355
        • Prentice R.L.
        Surrogate endpoints in clinical trials: definition and operational criteria.
        Stat Med. 1989; 8: 431-440
        • Stott S.L.
        • Hsu C.H.
        • Tsukrov D.I.
        • et al.
        Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.
        Proc Natl Acad Sci U S A. 2010; 107: 18392-18397
        • Lee J.J.
        • Lotze M.T.
        Molecular basis of metastasis.
        N Engl J Med. 2009; 360 (author reply 1679-80): 1679
        • Yu M.
        • Bardia A.
        • Wittner B.S.
        • et al.
        Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.
        Science. 2013; 339: 580-584

      CHORUS Manuscript

      View Open Manuscript